» Articles » PMID: 37710003

Distinct Monkeypox Virus Lineages Co-circulating in Humans Before 2022

Abstract

The 2022 global mpox outbreak raises questions about how this zoonotic disease established effective human-to-human transmission and its potential for further adaptation. The 2022 outbreak virus is related to an ongoing outbreak in Nigeria originally reported in 2017, but the evolutionary path linking the two remains unclear due to a lack of genomic data between 2018, when virus exportations from Nigeria were first recorded, and 2022, when the global mpox outbreak began. Here, 18 viral genomes obtained from patients across southern Nigeria in 2019-2020 reveal multiple lineages of monkeypox virus (MPXV) co-circulated in humans for several years before 2022, with progressive accumulation of mutations consistent with APOBEC3 activity over time. We identify Nigerian A.2 lineage isolates, confirming the lineage that has been multiply exported to North America independently of the 2022 outbreak originated in Nigeria, and that it has persisted by human-to-human transmission in Nigeria for more than 2 years before its latest exportation. Finally, we identify a lineage-defining APOBEC3-style mutation in all A.2 isolates that disrupts gene A46R, encoding a viral innate immune modulator. Collectively, our data demonstrate MPXV capacity for sustained diversification within humans, including mutations that may be consistent with established mechanisms of poxvirus adaptation.

Citing Articles

Strong and early monkeypox virus-specific immunity associated with mild disease after intradermal clade-IIb-infection in CAST/EiJ-mice.

Meyer Zu Natrup C, Clever S, Schunemann L, Tuchel T, Ohrnberger S, Volz A Nat Commun. 2025; 16(1):1729.

PMID: 39966381 PMC: 11836108. DOI: 10.1038/s41467-025-56800-2.


Comprehensive Insights into Monkeypox (mpox): Recent Advances in Epidemiology, Diagnostic Approaches and Therapeutic Strategies.

Kumar S, Guruparan D, Karuppanan K, Kumar K Pathogens. 2025; 14(1).

PMID: 39860962 PMC: 11768232. DOI: 10.3390/pathogens14010001.


Urogenital Manifestations in Mpox (Monkeypox) Infection: A Comprehensive Review of Epidemiology, Pathogenesis, and Therapeutic Approaches.

He S, Zhao J, Chen J, Liang J, Hu X, Zhang X Infect Drug Resist. 2025; 18():209-226.

PMID: 39816240 PMC: 11733167. DOI: 10.2147/IDR.S504280.


Evolutionary Analysis and Antiviral Drug Prediction of Mpox Virus.

Lian Z, Yang C, Qiu Y, Ge X Microorganisms. 2024; 12(11).

PMID: 39597628 PMC: 11596041. DOI: 10.3390/microorganisms12112239.


Viral infection and antiviral immunity in the oral cavity.

Hickman H, Moutsopoulos N Nat Rev Immunol. 2024; .

PMID: 39533045 DOI: 10.1038/s41577-024-01100-x.


References
1.
Ulaeto D, Agafonov A, Burchfield J, Carter L, Happi C, Jakob R . New nomenclature for mpox (monkeypox) and monkeypox virus clades. Lancet Infect Dis. 2023; 23(3):273-275. PMC: 9901940. DOI: 10.1016/S1473-3099(23)00055-5. View

2.
Rimoin A, Mulembakani P, Johnston S, Lloyd Smith J, Kisalu N, Kinkela T . Major increase in human monkeypox incidence 30 years after smallpox vaccination campaigns cease in the Democratic Republic of Congo. Proc Natl Acad Sci U S A. 2010; 107(37):16262-7. PMC: 2941342. DOI: 10.1073/pnas.1005769107. View

3.
Ogoina D, Iroezindu M, James H, Oladokun R, Yinka-Ogunleye A, Wakama P . Clinical Course and Outcome of Human Monkeypox in Nigeria. Clin Infect Dis. 2020; 71(8):e210-e214. DOI: 10.1093/cid/ciaa143. View

4.
Yinka-Ogunleye A, Aruna O, Dalhat M, Ogoina D, McCollum A, Disu Y . Outbreak of human monkeypox in Nigeria in 2017-18: a clinical and epidemiological report. Lancet Infect Dis. 2019; 19(8):872-879. PMC: 9628943. DOI: 10.1016/S1473-3099(19)30294-4. View

5.
Mauldin M, McCollum A, Nakazawa Y, Mandra A, Whitehouse E, Davidson W . Exportation of Monkeypox Virus From the African Continent. J Infect Dis. 2020; 225(8):1367-1376. PMC: 9016419. DOI: 10.1093/infdis/jiaa559. View